Nanjing Leads Biolabs Sets Out Board Composition and Committee Roles

An announcement from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) is now available.

Nanjing Leads Biolabs Co., Ltd. has announced the composition of its board of directors, detailing the mix of executive, non-executive and independent non-executive members and their specific roles. The leadership is led by chairman and CEO Dr. Kang Xiaoqiang, supported by directors with scientific and industry backgrounds, underlining a governance structure anchored in both management continuity and external oversight.

The company has also outlined the membership and chairpersons of its audit, nomination and remuneration committees, assigning key oversight roles to independent directors. This committee configuration is designed to enhance transparency, strengthen internal controls and align the company with prevailing corporate governance standards, which is relevant for investors monitoring board independence and oversight quality.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a biotechnology company based in Nanjing, China, listed in Hong Kong under stock code 9887. The company operates with a board structure that includes executive, non-executive, and independent non-executive directors, reflecting standard corporate governance practices in the biopharmaceutical and life sciences sector.

Its leadership team is headed by Dr. Kang Xiaoqiang, who serves concurrently as chairman, chief executive officer and general manager, signaling a centralized management role. The presence of multiple independent non-executive directors indicates an effort to ensure oversight, balanced decision-making and alignment with capital market governance expectations.

Average Trading Volume: 620,606

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$13.39B

For an in-depth examination of 9887 stock, go to TipRanks’ Overview page.